ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

Zacks Equity Research
Zacks Rank can tell you which stocks to buy and sell. Zacks Equity Research tells you why. Click here to learn more.

Quote:

Search for Ticker

Free Membership

Search:

MBRX: Metabasis Therapeutics Inc - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

METABASIS THERAPEUTICS INC (NASD)
MBRX	0.38	N/A	(N/A%)	Vol. 0	N/A ET

Metabasis Therapeutics, Inc. discovers and develops drugs for the treatment of liver diseases and metabolic diseases linked to pathways in the liver. They have established a broad pipeline of internally discovered product candidates using their proprietary technologies, NuMimetic and HepDirect.

General Information

METABASIS THERA

11119 North Torrey Pines Road La Jolla, CA 92037 Phone: 858 587-2770 Fax: 858 458-3504 Web: www.mbasis.com Email: bienfait@mbasis.com

Industry	MED-BIOMED/GENE
Sector:	Medical

Fiscal Year End	December
Last Reported Quarter	09/30/09
Next EPS Date	11/20/2009

Price and Volume Information

Zacks Rank
Yesterday's Close	0.38
52 Week High	1.15
52 Week Low	0.21
Beta	1.02
20 Day Moving Average	875,497.50
Target Price Consensus	.5

% Price Change
4 Week	-46.40
12 Week	-15.62
YTD	23.94

% Price Change Relative to S&P 500
4 Week	-46.98
12 Week	-20.45
YTD	2.57

Share Information
Shares Outstanding (millions)	35.16
Market Capitalization (millions)	13.94
Short Ratio	0.06
Last Split Date	N/A

Dividend Information
Dividend Yield	0.00%
Annual Dividend	$0.00
Payout Ratio	0.00
Change in Payout Ratio	0.00
Last Dividend Payout / Amount	NA / $0.00

EPS Information
Current Quarter EPS Consensus Estimate	-0.01
Current Year EPS Consensus Estimate	-0.14
Estimated Long-Term EPS Growth Rate	-
Next EPS Report Date	11/20/2009

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	3.00
30 Days Ago	3.00
60 Days Ago	3.00
90 Days Ago	3.00

Fundamental Ratios

P/E
Current FY Estimate:	-
Trailing 12 Months:	-
PEG Ratio	-

EPS Growth
vs. Previous Year	126.47%
vs. Previous Quarter	139.13%

Sales Growth
vs. Previous Year	248.07%
vs. Previous Quarter:	-49.75%

Price Ratios
Price/Book	4.91
Price/Cash Flow	-
Price / Sales	0.76

ROE
09/30/09	-2,761.79
06/30/09	-895.60
03/31/09	-484.41

ROA
09/30/09	-83.73
06/30/09	-104.99
03/31/09	-126.96

Current Ratio
09/30/09	3.29
06/30/09	0.96
03/31/09	0.78

Quick Ratio
09/30/09	3.29
06/30/09	0.96
03/31/09	0.78

Operating Margin
09/30/09	-67.68
06/30/09	-168.13
03/31/09	-685.34

Net Margin
09/30/09	-67.69
06/30/09	-168.11
03/31/09	-685.25

Pre-Tax Margin
09/30/09	-67.69
06/30/09	-168.11
03/31/09	-685.25

Book Value
09/30/09	0.08
06/30/09	-0.01
03/31/09	-0.11

Inventory Turnover
09/30/09	-
06/30/09	-
03/31/09	-

Debt-to-Equity
09/30/09	0.00
06/30/09	0.00
03/31/09	0.00

Debt to Capital
09/30/09	0.00
06/30/09	-
03/31/09	-


About Zacks \| Advertise \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2009 Zacks Investment Research